SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME eligible, "Median" or the "Company"), developer of eyonis®, a suite of artificial intelligence (AI) powered Software as Medical Devices (SaMD) for early cancer detection and diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, today announced that eyonis Inc., its U.S. subsidiary, will participate in the CHEST 2
eyonis Inc., a Median Technologies Company, to Present Study Results Supporting eyonis® LCS Performance Claims at CHEST 2026
